Chugai stops Gym329 obesity development, returns license and resumes SMA work
Reuters says Chugai Pharmaceutical Co Ltd is discontinuing development of Gym329 (Emugrobart) for obesity, returning the license and resuming development for SMA.
Reuters says Chugai Pharmaceutical Co Ltd is discontinuing development of Gym329 (Emugrobart) for obesity, returning the license and resuming development for SMA.